TCRX
TScan Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.33 / 10
Netural
Fund flow evaluation: 7.51/10 reflecting robust fund flow characteristics. Constructive Small trends face headwinds from adverse overall, block, Medium, Large, and Extra-large developments, indicating positive money flow direction. Analyst consensus points to predominantly positive analyst sentiment with moderate confidence. Distribution analysis: Strong Buy(66.7%), Neutral(33.3%) among 3 research opinions, supported by 1.16 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
67%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-13
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for TCRX?
- TCRX holds a Bearish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.33/10 (Netural).
